115 related articles for article (PubMed ID: 29061818)
21. Inhibition of interleukin-1β-induced endothelial tissue factor expression by the synthetic cannabinoid WIN 55,212-2.
Scholl A; Ivanov I; Hinz B
Oncotarget; 2016 Sep; 7(38):61438-61457. PubMed ID: 27556861
[TBL] [Abstract][Full Text] [Related]
22. The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells.
Morell C; Bort A; Vara D; Ramos-Torres A; Rodríguez-Henche N; Díaz-Laviada I
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):248-57. PubMed ID: 27324222
[TBL] [Abstract][Full Text] [Related]
23. [The effect of the activation of cannabinoid receptor on the proliferation and apoptosis of hepatoma HepG2 cells].
Wang Y; Zhou YT; Zhao Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Apr; 26(4):344-7. PubMed ID: 20368112
[TBL] [Abstract][Full Text] [Related]
24. Neuroprotective Action of the CB1/2 Receptor Agonist, WIN 55,212-2, against DMSO but Not Phenobarbital-Induced Neurotoxicity in Immature Rats.
Huizenga MN; Forcelli PA
Neurotox Res; 2019 Jan; 35(1):173-182. PubMed ID: 30141144
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoids Induce Cell Death and Promote P2X7 Receptor Signaling in Retinal Glial Progenitors in Culture.
Freitas HR; Isaac AR; Silva TM; Diniz GOF; Dos Santos Dabdab Y; Bockmann EC; Guimarães MZP; da Costa Calaza K; de Mello FG; Ventura ALM; de Melo Reis RA; França GR
Mol Neurobiol; 2019 Sep; 56(9):6472-6486. PubMed ID: 30838518
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid WIN 55,212-2 Inhibits Human Glioma Cell Growth by Triggering ROS-Mediated Signal Pathways.
Wang K; Wang Q; Li Q; Zhang Z; Gao J; Fan C; Sun B; Ni Q
Biomed Res Int; 2021; 2021():6612592. PubMed ID: 33977107
[TBL] [Abstract][Full Text] [Related]
27. [Cannabinoid WIN55, 212-2 inhibits proliferation, invasion and migration of human SMMC-7721 hepatocellular carcinoma cells].
Wang J; Deng Y; Tan Y; Li K; Wen B; Zhao Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 May; 32(5):619-24. PubMed ID: 27126940
[TBL] [Abstract][Full Text] [Related]
28. Cannabinoid receptor agonist WIN-55,212-2 protects differentiated PC12 cells from organophosphorus- induced apoptosis.
Sadri S; Bahrami F; Khazaei M; Hashemi M; Asgari A
Int J Toxicol; 2010; 29(2):201-8. PubMed ID: 20335515
[TBL] [Abstract][Full Text] [Related]
29. Synthetic cannabinoids and endometrial stromal cell fate: Dissimilar effects of JWH-122, UR-144 and WIN55,212-2.
Fonseca BM; Fernandes R; Almada M; Santos M; Carvalho F; Teixeira NA; Correia-da-Silva G
Toxicology; 2019 Feb; 413():40-47. PubMed ID: 30502353
[TBL] [Abstract][Full Text] [Related]
30. WIN55,212-2-Induced Expression of Mir-29b1 Favours the Suppression of Osteosarcoma Cell Migration in a SPARC-Independent Manner.
Notaro A; Emanuele S; Geraci F; D'Anneo A; Lauricella M; Calvaruso G; Giuliano M
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652569
[TBL] [Abstract][Full Text] [Related]
31. Effects of the cannabinoid receptor agonist WIN 55,212-2 on operant behavior and locomotor activity in rats.
Drews E; Schneider M; Koch M
Pharmacol Biochem Behav; 2005 Jan; 80(1):145-50. PubMed ID: 15652390
[TBL] [Abstract][Full Text] [Related]
32. Cannabinoid WIN-55,212-2 mesylate inhibits interleukin-1β induced matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase expression in human chondrocytes.
Dunn SL; Wilkinson JM; Crawford A; Le Maitre CL; Bunning RA
Osteoarthritis Cartilage; 2014 Jan; 22(1):133-44. PubMed ID: 24211233
[TBL] [Abstract][Full Text] [Related]
33. The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner.
Curran NM; Griffin BD; O'Toole D; Brady KJ; Fitzgerald SN; Moynagh PN
J Biol Chem; 2005 Oct; 280(43):35797-806. PubMed ID: 16105834
[TBL] [Abstract][Full Text] [Related]
34. Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells.
Burgos E; Gómez-Nicola D; Pascual D; Martín MI; Nieto-Sampedro M; Goicoechea C
Eur J Pharmacol; 2012 May; 682(1-3):62-72. PubMed ID: 22374260
[TBL] [Abstract][Full Text] [Related]
35. Effects of WIN 55,212-2 (a synthetic cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant activity of various novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
Florek-Luszczki M; Wlaz A; Zagaja M; Andres-Mach M; Kondrat-Wrobel MW; Luszczki JJ
Pharmacol Biochem Behav; 2015 Mar; 130():53-8. PubMed ID: 25592741
[TBL] [Abstract][Full Text] [Related]
36. The cannabinoid WIN 55212-2 mitigates apoptosis and mitochondrial dysfunction after hypoxia ischemia.
Alonso-Alconada D; Alvarez A; Alvarez FJ; Martínez-Orgado JA; Hilario E
Neurochem Res; 2012 Jan; 37(1):161-70. PubMed ID: 21909954
[TBL] [Abstract][Full Text] [Related]
37. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
38. Cannabinoid WIN-55,212-2 mesylate inhibits tumor necrosis factor-α-induced expression of nitric oxide synthase in dorsal root ganglion neurons.
Tan R; Cao L
Int J Mol Med; 2018 Aug; 42(2):919-925. PubMed ID: 29786105
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid WIN55, 212-2 induces cell cycle arrest and inhibits the proliferation and migration of human BEL7402 hepatocellular carcinoma cells.
Xu D; Wang J; Zhou Z; He Z; Zhao Q
Mol Med Rep; 2015 Dec; 12(6):7963-70. PubMed ID: 26500101
[TBL] [Abstract][Full Text] [Related]
40. CB1 receptor-dependent and -independent inhibition of excitatory postsynaptic currents in the hippocampus by WIN 55,212-2.
Németh B; Ledent C; Freund TF; Hájos N
Neuropharmacology; 2008 Jan; 54(1):51-7. PubMed ID: 17714744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
